SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is gaining traction as a cryptocurrency merging blockchain with cannabis culture, sparking interest in its potential for growth and innovation. Community members are actively sharing contract addresses and celebrating the coin's unique identity. The coin is presented as more than just a currency, but a movement towards freedom and cultural expression within the digital space.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the community anticipates a potential surge driven by the historical performance of "Uptober" and speculation around pending ETF approvals. Discussions also highlight the potential impact of the government shutdown, with some viewing Bitcoin as a safe haven amid economic uncertainty. Some users are highlighting specific crypto stocks to watch for potential growth.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending amid positive sentiment around Ethereum, with the community anticipating a potential rally and discussing the company's growing ETH holdings. Talk of a government shutdown and its potential impact on crypto is circulating, with some expecting BMNR to benefit. Technical analysis and predictions of significant price increases are also contributing to the heightened interest.

Ethereum is a global, open-source platform for decentralized applications. In other words, the vision is to create a world computer that anyone can build applications in a decentralized manner; while all states and data are distributed and publicly accessible. Ethereum supports smart contracts in which developers can write code in order to program digital value. Examples of decentralized apps (dapps) that are built on Ethereum includes tokens, non-fungible tokens, decentralized finance apps, lending protocol, decentralized exchanges, and much more.  On Ethereum, all transactions and smart contract executions require a small fee to be paid. This fee is called Gas. In technical terms, Gas refers to the unit of measure on the amount of computational effort required to execute an operation or a smart contract. The more complex the execution operation is, the more gas is required to fulfill that operation. Gas fees are paid entirely in Ether (ETH), which is the native coin of the blockchain. The price of gas can fluctuate from time to time depending on the network demand.

Ethereum

Ethereum is trending as the crypto market anticipates a potentially bullish "Uptober," with community members eyeing targets around $4500 and beyond. Talk centers around the potential for a short squeeze, with some pointing to Tom Lee's long-term price predictions and recent treasury activity as bullish catalysts. However, some traders remain cautious, citing technical indicators and potential pullbacks amid broader market uncertainty.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the crypto community discusses potential catalysts for a price surge in October, including speculation around ETF approvals and the impact of a possible government shutdown. Some traders are weighing short-term bearish possibilities against the longer term outlook. Community members are also analyzing XRP's relationship with broader crypto market trends and developments with SWIFT.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as the government shutdown looms, sparking debate about its potential impact on the market. While some traders anticipate a dip, drawing parallels to past shutdowns that saw gains, others believe current high valuations make this situation different. The community is weighing the potential for market volatility against historical trends, with some eyeing safe-haven assets.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the possibility of a government shutdown looms, with the community debating its potential market impact. While some anticipate a downturn, others believe the shutdown's effects are already priced in or view it as a catalyst for a rally. Some traders are closely monitoring technical levels and option activity, while others express concerns about broader economic issues and market manipulation.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending following the release of its Q1 earnings report, which showed a surprise rise in revenue and beat expectations, signaling that the company's turnaround efforts are gaining traction. Despite positive results, concerns remain around weakness in China and the impact of tariffs, leading to mixed sentiment among investors. The community is actively discussing whether the positive earnings will hold, with some anticipating a move towards $80 and others expecting a pullback due to broader market conditions and concerns about guidance.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Conversations around DJT are currently focused on the U.S. government shutdown and its potential impact, with community members debating which party is responsible. Some are discussing Trump's recent statements and actions, including those related to the military and trade, and how they might affect the stock. There's also discussion around the proposed TrumpRx initiative and its potential impact on the pharmaceutical industry.

Draganfly, Inc. engages in the manufacture and sale of commercial unmanned aerial vehicle systems and software serving the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. Its products include quad-copters, fixed wing aircrafts, ground based robots, hand held controllers, and software used for tracking, live streaming, and data collection. The firm also offers custom engineering, training, simulation consulting, as well as data and flight training services. The company was founded by Zenon Dragan and Christine Dragan in 1998 and is headquartered in Saskatoon, Canada.

Draganfly Inc

Draganfly ($DPRO) is trending due to increased community interest and positive sentiment around its potential in the drone and AI/IoT sectors, particularly following news of a US Army deal. Traders are actively discussing the stock's low float and potential for a short squeeze, with many anticipating significant upside and contract details to drive the price higher. Some see it as undervalued compared to other drone companies, like $RCAT and $ONDS.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fractyl Health (GUTS) announced on Friday that patients who stopped taking the GLP-1 class drug Tirzepatide and were treated with its Revita lost an additional 2.5% of their total body weight at three months in a trial. At the time of writing, shares of the company traded 28% higher on Friday afternoon.The study was designed to evaluate the Revita procedure in adults with obesity who achieved at least 15% total body weight loss with Tirzepatide, the active ingredient in Eli Lilly’s blockbuster weight loss drug Zepbound. Those who received a sham procedure after discontinuing Zepbound regained 10% total body weight in the study at three months, the company said.Revita is Fractyl’s lead product candidate. The procedure is designed to reverse damage to intestinal nutrient-sensing and signaling mechanisms caused by chronic high-fat and high-sugar diets by remodeling the inner wall of the first part of the small intestine.“These results are clinically and statistically significant and provide randomized, blinded evidence that drug-free, durable weight maintenance is possible,” the company said, while adding that the study also supports Revita in post-GLP-1 weight maintenance.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/26/3156942/0/en/Fractyl-Health-Announces-Groundbreaking-Data-from-REMAIN-1-Midpoint-Cohort-Showing-Revita-Maintained-Weight-Loss-After-GLP-1-Discontinuation.html">stated</a> that no serious adverse events related to Revita were identified in the study, and side effects were infrequent and mild. The firm expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.On Friday, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/26/3156951/0/en/Fractyl-Health-Announces-Pricing-of-60-Million-Underwritten-Offering-of-Common-Stock.html">announced</a> the pricing of an underwritten offering of 60 million shares of its common stock at $1.00 per share, representing a discount of about 1% from the stock’s closing price on Thursday. The gross proceeds from the offering are expected to be about $60 million, the company added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/GUTS">GUTS stock</a> rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:622/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_26_at_1_00_54_PM_png_90a4342a59.webp" alt="GUTS' Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 26, 2025 | Source: Stocktwits" width="622" height="66"><figcaption>GUTS' Sentiment Meter and Message Volume as of 1:01 p.m. ET on Sept. 26, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed disappointment at the offering.<stembedurl>https://stocktwits.com/Stmkr/message/630122910</stembedurl>GUTS stock is down 38% this year and by about 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uber-reportedly-expects-non-restaurant-deliveries-to-surge-faster-than-previously-expected/chDVlUmR3eW">Uber Reportedly Expects Non-Restaurant Deliveries To Surge Faster Than Previously Expected</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

GUTS Stock Rallied About 28% Today – Here’s Why

Fractyl Health expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.

Equity

Fractyl Health expects to file with the U.S. Food and Drug Administration for the approval of Revita in the second half of 2026.


Fractyl Health shares fell 27% in after-hours trading Tuesday after the company announced a public offering of common stock and pre-funded warrants.&nbsp;The offering includes accompanying common warrants, and Ladenburg Thalmann is acting as&nbsp;the sole book-running manager.Despite the market’s negative reaction to the capital raise, retail sentiment on Stocktwits remained optimistic, buoyed&nbsp;by the release of strong new clinical data hours earlier.&nbsp;The company shared two-year follow-up results from the Germany Real-World Registry study, which evaluated the Revita procedure in people with obesity and advanced type 2 diabetes (T2D) who had inadequately controlled glucose levels despite being on up to three glucose-lowering agents (GLAs).According to the study, a single Revita procedure led to a median weight loss of 9.6%, sustained over two years, with weight decreasing from 104 kg to 97 kg at year one and remaining stable through year two.&nbsp;Notably, 7 of 8 participants achieved at least a 5% weight reduction, and 5 of 8 saw reductions of 10% or more. Only one participant, who had a history of cortisone therapy known to cause weight gain, experienced&nbsp;a modest weight increase.Meanwhile, median HbA1c decreased from 9.6% to 7.2%, which was maintained over two years of follow-up. Patients were also able to reduce or stabilize the dosing of GLAs, and there were no device or procedure-related serious adverse events.Fractyl said the findings support the potential of Revita as a long-lasting, non-drug metabolic therapy and build momentum for its ongoing U.S. pivotal trial, REMAIN-1, which is under an IDE and is designed to assess Revita for weight maintenance after GLP-1 treatment.&nbsp;The company expects Midpoint Cohort data in the third quarter and primary endpoint data from the Pivotal Cohort in the second half of&nbsp; 2026.As of now, 34 patients are enrolled in the Germany registry, which is no longer recruiting but will continue with protocol-defined follow-up. Weight loss and glycemic benefits were observed as early as one month post-procedure and persisted throughout the study duration.Fractyl intends to use net proceeds from the offering, along with existing cash, to support both the Revita and Rejuva pipeline programs, and for working capital and general corporate purposes.On Stocktwits,&nbsp;<a href="https://stocktwits.com/symbol/GUTS">retail sentiment for Fractyl</a> was ‘extremely bullish’ amid a 124% surge in 24-hour message volume.One user said the strong two-year Revita data was a “big win” and that similar setups, including positive clinical news followed by a quick offering, have historically seen shares recover to pre-offering levels.&nbsp;While the user noted the company “could have done the PR’ing/offering a bit better,” they added the underlying science was “phenomenal” and called Revita a “first-in-class” product with major potential.<stembedurl>https://stocktwits.com/BioRich/message/623885253</stembedurl>Another user said they were buying into Fractyl, looking for either a short squeeze or a potential buyout.<stembedurl>https://stocktwits.com/garygb/message/623881828</stembedurl>Fractyl’s stock has declined 12.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Fractyl Health (GUTS) shares fell 27% in after-hours trading Tuesday after the company announced a public offering of common stock and pre-funded warrants. (Photo credit: Getty Images)

Fractyl Health Sinks After-Hours On Stock Offering, But Investors Cheer Durable Weight Loss Data

Retail optimism surged following new real-world data showing that patients with advanced type 2 diabetes sustained weight loss and glycemic improvements two years after a single Revita procedure.

Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company ), a metabolic therapeutics company focused on pioneering new approaches for the treatment of...

Fractyl Health reports Q4 EPS ($11.18) vs ($7.39) last year

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Received IDE approval for the Revita Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal...

Fractyl Health Gains FDA Nod to Investigate Revita Device

Fractyl Health, Inc. (GUTS) just unveiled an update.

Fractyl Health, Inc. has announced a significant milestone with the FDA granting it Investigational Device Exemption to explore the effectiveness...

Fractyl Health Receives FDA IDE Approval for the Revita  Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Revita aims to be the first approved therapeutic option for durable weight maintenance after discontinuation of GLP-1 based drugs, as an adjunct to diet and exercise With this FDA IDE approval...

Fractyl Health receives FDA IDE approval for Revita Remain-1 pivotal study

Fractyl Health (NASDAQ:GUTS) Stock Price Down 6.2%

Fractyl Health, Inc. (NASDAQ:GUTS  Get Free Report)s stock price was down 6.2% during trading on Wednesday . The company traded as low as $7.10 and last traded at $7.20. Approximately...

Fractyl Health announces results from Rejuva platform

Fractyl Health, Inc. is a metabolic therapeutics company. It develops medical device solutions for the treatment of metabolic diseases, which includes type 2 diabetes and obesity. The company was founded by Harith Rajagopalan and Jay D. Caplan on August 30, 2010 and is headquartered in Burlington, MA.

Fractyl Health Inc.

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$1.59
Prev Close	$1.50
Open	$1.50
Dividend Yield	0.00%
50-Day Moving Average	$1.21
Beta	1.11
Avg. Volume	1.42M
PE Ratio	-0.73

52-Week High	$3.48
52-Week Low	$0.825
Market Capitalization	$108.29M
EPS (Annual)	-$1.44
Price to Book	-4.11
Revenue Per Employee	$869.16
Enterprise Value/EBITDA	N/A

GUTS
Fractyl Health Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GUTS News

GUTS Fractyl Health Inc.